Long term oral Dantrolene Improved Muscular Symptoms in a Malignant Hyperthermia Susceptible Individual

Journal of Neuromuscular Diseases

Volumn 3, Issue 1, 2016, Pages 115-119

  Butala, Brian N ^a   Kang, Audry ^b   Guron, Jasmeen ^c   Brandom, Barbara W ^b,c  

^a WESTERN PENNSYLVANIA HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c MERCY HOSPITAL OF PITTSBURGH   (United States)

Author keywords

malignant hyperthermia (MH) susceptibility; myalgia dantrolene; Skeletal muscle ryanodine receptor (RYR1) gene

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; DANTROLENE; HALOTHANE; LACTATE DEHYDROGENASE; RYANODINE RECEPTOR 1; CENTRAL MUSCLE RELAXANT; RYANODINE RECEPTOR;

ADULT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BEDTIME DOSAGE; CASE REPORT; CAUSE OF DEATH; CLINICAL ARTICLE; CREATINE KINASE BLOOD LEVEL; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ELECTROMYOGRAPHY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LACTATE DEHYDROGENASE BLOOD LEVEL; LEG CRAMP; MALIGNANT HYPERTHERMIA; MUSCLE BIOPSY; PAROTIDECTOMY; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RYR1 GENE; SENSITIVITY AND SPECIFICITY; SPINAL ANESTHESIA; TREATMENT RESPONSE; VAGINAL DELIVERY; CHRONIC PAIN; COMPLICATION; METABOLISM; MUSCLE CRAMP; MYALGIA;

ADULT; CHRONIC PAIN; CREATINE KINASE; DANTROLENE; FEMALE; HUMANS; MALIGNANT HYPERTHERMIA; MUSCLE CRAMP; MUSCLE RELAXANTS, CENTRAL; MYALGIA; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL;

EID: 85016461190     PISSN: 22143599     EISSN: 22143602     Source Type: Journal    
DOI: 10.3233/JND-150130     Document Type: Article

References (25)

1. Gronert GA. Malignant hyperthermia. Anesthesiology. 1980; 53(5): 359-423.
2. Tobin JR, Jason DR, Challa VR, Nelson TE, Sambuughin N. Malignant hyperthermia and apparent heat stroke. JAMA. 2001; 286(2): 168-9.
3. Sambuughin N, Capacchione J, Blokhin A, Bayarsaikhan M, Bina S, Muldoon S. The ryanodine receptor type 1 gene variants in African American men with exertional rhabdomyolysis and malignant hyperthermia susceptibility. Clin Genet. 2009; 76(6): 564-8.
4. Brandom BW, Muldoon SM. Unexpected MH deaths without exposure to inhalation anesthetics in pediatric patients. Pediatric Anesth. 2013; 23(9): 851-4.
5. Potts LE, Longwell JJ, Dedocks P, et al. Improving awareness of nonanesthesia-related malignant hyperthermia presentations: A tale of two brothers. A &A Case Reports. 2014; 3: 23-6.
6. Dlamini N, Voermans NC, Lillis S, et al. Mutations in RYR1 are a common cause of exertional myalgia and rhabdomyolysis. Neuromuscular Disord. 2013; 23(7): 540-8.
7. Paul-Pletzer K, Yamamoto T, Manjunatha BB, et al. Identification of a dantrolene-binding sequence on the skeletal muscle ryanodine receptor. J Biol Chem. 2002; 277: 34918-23.
8. Saadet I, Wei H. The cytoprotective effects of dantrolene: A ryanodine receptor antagonist. Anesth and Analg. 2010; 111: 1400-10.
9. Flewellen EH, Nelson TE, Jones WP, et al. Dantrolene dose response in awake man: Implications for management of malignant hyperthermia. Anesthesiology. 1983; 59: 275-80.
10. Kheder A, Nair NP. Spasticity: Pathophysiology, evaluation and management. Pract Neurol. 2012; 12(5): 289-98.
11. Allen GC, Cattran CB, Peterson RG, Lalande M. Plasma levels of dantrolene following oral administration in malignant hyperthermia-susceptible patients. Anesthesiology. 1988; 69(6): 900-4.
12. Ogletree JW, Antognini JF, Gronert GA. Postexercise muscle cramping associated with positive malignant hyperthermia contracture testing. Am J Sports Med. 1996; 24: 49-51.
13. Wadhwa RK, Tantisira B. Parotidectomy in a patient with a family history of Hyperthermia. Anesthesiology. 1974; 40(2): 191-4.
14. Wadhwa RK. Obstetric anesthesia for a patient with malignant hyperthermia susceptibility. Anesthesiology. 1977; 46: 63-4.
15. Hoyer A, Vesser M, et al. Low-dose dantrolene improves muscle function in walking MHS person. Anesthesiology. 2004; 101: A1163.
16. Sambuughin N, HolleyH, Muldoon S, et al. Screening of the entire ryanodine receptor type 1 coding regions for sequence variants associated with malignant hyperthermia susceptibility in the North American population. Anesthesiology. 2005; 102(3): 515-21.
17. Timmins MA, Rosenberg H, Larach MG, et al. Malignant Hyperthermia testing in probands without adverse anesthetic reaction. Anesthesiology. 2015; 123(5): 548-56.
18. Dykes MH. Evaluation of a muscle relaxant: Dantrolene Sodium (Dantrium). JAMA. 1975; 231: 862-4.
19. Krach LE. Pharmacotherapy of spasticity: Oral medications and intrathecal Baclofen. J Child Neurol. 2001; 16(1): 31-6.
20. Chan CH. Dantrolene sodium and hepatic injury. Neurology. 1990; 40(9): 1427-32.
21. Stowell KM. DNA Testing for Malignant Hyperthermia: The reality and the dream. Anes Analg. 2014; 118(2): 397-406.
22. Levano S, Vukcevic M, Singer M, et al. Increasing the number of diagnostic mutations in malignant hyperthermia. Hum Mutat. 2009; 30(4): 590-8.
23. Monnier N, Kozak-Ribbens G, Krivosic-Horber R, et al. Correlations between genotype and pharmacological, histological, functional, and clinical phenotypes in malignant hyperthermia susceptibility. Hum Mutat. 2005; 26(5): 413-25.
24. Ohtaki E, Komori H, Yamaguchi Y, Matsuishi T. Successful dantrolene sodium treatment of a patient with myotonia congenital (Thomsen's disease). Acta Paediatr Jpn. 1991; 33(5): 668-71.
25. Vissing J, Schmalbruch H, Haller RH, Clausen T. Muscle Phosphoglycerate mutase deficiency with tubular aggregates: Effect of dantrolene. Annal Neurol. 1999; 46(2): 274-7.